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Abstract: Fluoropyrimidines, such as capecitabine and 5-fluorouracil, may cause cardiac 
toxicity. In recent years, the incidence of this side effect has increased and it is expected to further 
rise due to the population aging and the disproportionate incidence of breast and gastrointestinal 
cancers in older individuals. The spectrum of cardiac manifestations includes different signs and 
symptoms and the diagnosis may be difficult. Here, we report the case of a 43-year-old woman 
with advanced breast cancer who was rechallenged with a capecitabine-based regimen after 
experiencing a cardiac adverse event during the first fluoropyrimidine exposure. This real-practice 
case serves as a springboard for discussion about the current evidence on differential diagnosis 
of capecitabine-related cardiac toxicity, its risk factors, and the underpinning mechanisms of 
early onset. Moreover, we discussed whether a rechallenge with fluoropyrimidines could be safe 
in patients who had experienced a previous cardiac adverse event.
Keywords: risk factors, clinical manifestation, rechallenge
Introduction
Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), is an orally available fluoro-
pyrimidine analog selectively activated through a three-step enzymatic process. The 
final transformation is catalyzed by thymidine phosphorylase, an enzyme with higher 
activity in tumors than in normal tissues.1 Thus, after its administration, 5-FU levels 
are higher in tumor cells than in the systemic circulation.1,2
Capecitabine has a well-documented safety profile; the most commonly reported 
side effects are hand–foot syndrome (17%), diarrhea (17%), and nausea (15%), but all 
these toxicities are usually manageable and reversible.1,3 Although well tolerated, both 
capecitabine and its parental compound may induce cardiotoxicity, whose incidence is 
increasing due to the aging of the population.4 The spectrum of cardiac effects includes 
blood pressure disorders, acute coronary syndromes, arrhythmias, heart failure with 
cardiogenic shock, and even sudden death.5
Our real-practice paradigmatic case of capecitabine-related cardiotoxicity is help-
ful in summarizing the current evidence on this important safety concern (differential 
diagnosis, mechanisms of onset, risk factors) and serves as an example to discuss the 
safety of fluoropyrimidine rechallenge after a first cardiac episode.
Presentation of case
First cardiac event
A 43-year-old premenopausal woman was diagnosed in July 2006 with a locally 
advanced (stage IIIA, cT3 cN1 M0),6 hormone receptors-positive (estrogen receptor 
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[ER] 40% of positive cells, progesterone receptor [PgR] 
50% of positive cells), and human epidermal growth factor 
receptor (HER)2-positive (immunohistochemistry score 3+) 
invasive ductal carcinoma of the left breast. The Ki67/MIB-1 
immunostaining was positive in 32% of cancer cells. At the 
time of primary diagnosis, the patient was a light smoker (less 
than five packs per year) with a family history of hypertension 
and ischemic heart disease; no other risk factors for cardiac 
disease were reported.
On August 2, 2006, the patient was randomized into 
the neoadjuvant ECTO II (European Cooperative Trial in 
 Operable breast cancer – second) trial7 and she was allocated 
to receive exemestane 25 mg/day orally plus four cycles of 
doxorubicin 60 mg/m² intravenously (iv);  cyclophosphamide 
600 mg/m² iv at 3-week intervals (AC) followed by four 
cycles of paclitaxel 100 mg/m² iv on days 1 and 8; and 
capecitabine 1,850 mg/m² orally in divided doses from day 1 
to 14 at 3-week intervals (TX).
The AC regimen was well tolerated, without any cardio-
vascular complaint.
In November 2006, during the first cycle of TX regimen, 
she presented at the Emergency Ward of the University 
Hospital of Udine, Italy, to investigate a recurrent, sharp, 
nonradiating retrosternal chest pain, which had started 
24 hours previously. The pain lasted up to 20 minutes 
and was unrelated to meals and exercises, whereas it was 
relieved by a change of position. Blood pressure, pulse rate, 
and body temperature were normal. No pericardial friction 
rub, added heart sounds, or other abnormalities were observ-
able through auscultation. Blood count, lactate dehydroge-
nase, transaminases, serum C-reactive protein (CRP), serum 
creatine phosphokinase, and creatine phosphokinase-MB 
fraction were all within normal limits. However, the plasma 
troponin I (TnI) concentration was 0.27 ng/mL (normal 
levels #0.04 ng/mL) and the continuous 12-lead electro-
cardiogram (ECG) Holter monitoring showed concave ST 
segment elevation in multiple leads, biphasic T wave inver-
sion, and peaked T wave elevation (Figure 1). The ratio of ST 
segment elevation to T wave amplitude in lead V6 was 0.4. 
The electrocardiographic findings suggested the possibility 
of an acute pericarditis, although elevated TnI concentration 
was not concordant with the diagnosis.
A second cardiac evaluation was performed with a 
two-dimensional echocardiogram (2D Echo) that showed 
inferoposterior hypokinesis, with preserved global ventricular 
size and function; mild aortic and mitral regurgitation were 
also observed, with normal left atrium and absence of pericar-
dial effusion. The final diagnosis was acute myopericarditis, 
and anti-inflammatory treatment with acetylsalicylic acid 
800 mg twice a day for 1 month was started. The following 
day, white blood-cell count and serum CRP were confirmed 
to be normal, and plasma TnI level was 0.12 ng/mL. Two days 
later, a multigated acquisition scan showed normal regional 
kinetics, with a left ventricular ejection fraction of 67%, 
and normal ECG tracing. However, the TX neoadjuvant 
treatment was interrupted and the patient was referred for 
breast surgery.
The patient improved soon after capecitabine 
discontinuation. In light of this prompt resolution, 
a  fluoropyrimidine-induced cardiotoxicity was strongly 
suspected. The investigators did not perform a myocardial 
biopsy due to the invasive nature of this procedure.
After radical left mastectomy, a ypT2 ypN1mi, hormone 
receptors-positive (in this case, a semiquantitative evaluation 
of ER and PgR was calculated using the H-score: ER H-score 
30; PgR H-score 15), HER2-positive tumor was detected, 
with a Ki67/MIB-1 proliferation index that resulted positive 
in 32% of cancer cells. Both ECG and 2D Echo showed no 
abnormalities, with preserved left ventricular size and func-
tion, and a left ventricular ejection fraction of 64%. Therefore, 
the patient was offered adjuvant endocrine treatment and 
trastuzumab 6 mg/kg (8 mg/kg loading dose) iv every 3 weeks 
for 1 year. For safety reasons, trastuzumab was always infused 
within 90 minutes. From February 2007 to February 2008, 
the patient received a total of 18 trastuzumab administrations, 
without any cardiac complications.
Also, the patient underwent irradiation of the lymphatic 
drainage area, while excluding chest wall irradiation.
second cardiac event
One year later, the patient was diagnosed with sternum 
and liver metastases and received first-line treatment with 
six cycles of docetaxel plus trastuzumab, followed by 
trastuzumab single agent. At disease progression, a second-
line chemotherapy with lapatinib and capecitabine was 
planned.
Fluoropyrimidines rechallenge was attempted with 
reduced dose of capecitabine: 1,000 mg/m2/day, instead of 
2,000 mg/m2/day,8 orally from day 1 to day 14 every 3 weeks. 
Moreover, a cardiac surveillance with daily 12-lead ECG, 
24-hour ECG Holter monitoring on the 4th day of chemo-
therapy, and treadmill stress test on the 5th day was planned 
in order to detect early signs of cardiac toxicity.
On March 1, 2010, the patient received the first dose 
of lapatinib 1,250 mg/day continuously plus capecitabine 
1,000 mg/m2/day, from day 1 to day 14, every 21 days. 
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Five days later,  during 24-hour ECG Holter monitoring, she 
was admitted at the Emergency Ward of a General Hospital 
(20 miles away from our University Hospital) due to short 
recurrent episodes of atypical chest and abdominal pain, 
associated with jugular constriction. No abnormalities 
were underlined with physical examination, 12-lead ECG, 
and 2D Echo. The plasma TnI concentration was less than 
0.005 ng/mL, within the range of normality.
The Holter monitoring showed electrocardiography fea-
tures consistent with Prinzmetal’s angina: heart rate ranged 
from 45 to 137 beats/minute and transitory ischemic ECG 
changes, such as ST segment depression and elevation, and 
T wave negative inversion or peaked elevation (Figure 2A–B). 
Particularly, an infero-antero-lateral 4 mm ST segment 
elevation was observed from 7.20 am to 7.50 am, while the 
patient was asymptomatic (Figure 3). The patient received 
amlodipine 10 mg, sublingual nitrates, and acetylsalicylic 
acid 100 mg and was discharged 24 hours later.
In order to rule out atherosclerotic coronary artery disease 
and to better define the first episode of cardiotoxicity, the patient 
underwent coronary artery computed tomography, which 
showed normal arteries, and cardiac magnetic resonance, which 
did not show any sign of acute or previous myocarditis.
According to the strong suspicion of capecitabine-induced 
cardiotoxicity, the second-line treatment was changed to 
vinorelbine 25 mg/m² plus trastuzumab 2 mg/kg weekly.
Discussion
Differential diagnosis between capecitabine-related cardio-
toxicity and other cardiac abnormalities.
Figure 1 First cardiac event.
Notes: Traces from the 12-lead eCG (25 mm/s, 10 mm/mV)  showed transient abnormalities. peaked T wave and sT segment elevation were associated with thoracoabdominal 
discomfort. I, II, and III = limb leads; V1 to V6 = precordial leads.
Abbreviations: aVF, lead augmented vector foot; aVL, lead augmented vector left; aVR, lead augmented vector right; eCG, electrocardiogram.
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First cardiac event
During neoadjuvant treatment, clinical symptoms, TnI eleva-
tion, ECG findings (widespread ST segment elevation and T 
wave inversion without development of Q waves), and regional 
hypokinesia at 2D Echo suggested a possible diagnosis of acute 
myopericarditis.9 Nevertheless, blood tests showing a normal 
leukocyte and eosinophil count, with no elevation of CRP, were 
against this hypothesis and supportive of capecitabine-induced 
cardiotoxicity. Even if the hypothesis of acute myopericarditis 
would be accepted, the viral etiology could not be excluded, 
since serum antibodies against the most common viruses 
(ie, echovirus and coxsakievirus) were not checked.
Signs and symptoms experienced by the patient may also 
suggest an acute coronary syndrome or a Takotsubo syndrome, 
Figure 2 second cardiac event.
Notes: Traces from the continuous 12-lead 24 hours eCG Holter monitoring (25 mm/s, 10mm/mV) showed transient abnormalities. (A) Heart rate 75 bpm: sT segment 
depression; (B) Heart rate 81 bpm: asymptomatic T wave negative inversion. I, II, and III = limb leads; V1 to V6 = precordial leads.
Abbreviations: aVF, lead augmented vector foot; aVL, lead augmented vector left; aVR, lead augmented vector right; eCG, electrocardiogram.
I
II
III
aVR
aVL
aVF
B
V6
V5
V4
V3
V2
V1
Cardiac frequency: 81
I
II
III
aVR
aVL
aVF V6
V5
V4
V3
V2
V1
A Cardiac frequency: 75
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
8.
11
0.
18
6.
19
9 
on
 0
1-
De
c-
20
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1787
Capecitabine-induced cardiotoxicity
both linked with 5-FU and capecitabine administration.10–14 
In particular, capecitabine has been reported to trigger api-
cal and midventricular Takotsubo syndrome characterized 
by ECG signs of ST elevation myocardial infarction, severe 
left ventricular dysfunction, and cardiogenic shock.13 Unlike 
acute myocardial infarction, Takotsubo syndrome is gener-
ally reversible in a short period and it is not associated with 
significant coronary artery disease. Catecholamine-induced 
cardiotoxicity, microvascular dysfunction, and a perfusion/
metabolism mismatch, such as in postischemic myocardial 
stunning, are the most common pathogenic events involved 
in Takotsubo syndrome.14 Of note, acute 2D Echo pattern 
showed inferoposterior hypokinesis and it was incongru-
ous with apical and midventricular transient left ventricular 
dysfunction syndrome.
Delayed anthracyclines toxicity could have been also 
considered, since anthracyclines have been occasionally 
associated with the occurrence of a myocarditis–pericarditis 
syndrome.15 However, this rare syndrome has been described 
within 1 month from the first anthracyclines administration.16 
In our patient, the cardiac symptomatology appeared more 
than 3 months after the first infusion of doxorubicin and had 
a benignant course; moreover, both the ECG tracing and the 
echocardiography were normal at the end of anthracycline-
based chemotherapy.
second cardiac event
The second episode was characterized by atypical chest 
pain without detectable changes on ECG tracing.  However, 
24-hour Holter monitoring documented a number of 
transitory ischemic ST segment deviation and T wave 
abnormalities.
Transitory ST segment elevation or depression and 
T wave inversion, especially if they occurred in the early 
morning hours, should be considered consistent with 
vasospastic angina.17,18 As demonstrated in animal models and 
in human studies,19,20 arterial vasospasm is one of the possible 
mechanisms of 5-FU related angina. During a capecitabine-
related coronary spasm, patients may experience angina-like 
chest pain21,22 and ventricular fibrillation.23,24 Moreover, 
the diagnosis of vasospastic angina could be consistent with 
the hypothesis of an acute coronary syndrome also in the first 
cardiac event presented during neoadjuvant treatment.
Nevertheless, similar ST segment abnormalities may also 
be observed in acute myocardial infarction, acute pericarditis, 
myopericarditis, and Prinzmetal’s angina.25
The milder symptoms during the second episode are 
justified by the shorter exposure time and the lower dose 
of capecitabine administrated. In fact, the incidence of 
cardiac toxicity of fluoropyrimidines depends on both 
the cumulative dose of drug stored within the heart and 
Cardiac frequency: 0
I
II
III
aVR
aVL
aVF
V4
V3
V2
V1
V5
V6
Figure 3 second cardiac event.
Notes: Trace from the continuous 12-lead 24 hours eCG Holter monitoring (25 mm/s, 10mm/mV) showed: Heart rate 100 bpm, 4 mm asymptomatic sT segment elevation. 
I, II, and III = limb leads; V1 to V6 = precordial leads.
Abbreviations: aVF, lead augmented vector foot; aVL, lead augmented vector left; aVR, lead augmented vector right; eCG, electrocardiogram.
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the clearance of the active metabolites from tissues in the 
individual patient. For this reason, the cardiotoxic effects 
may even last days after withdrawing the drug.26 The dif-
fuse hypokinesia detected with 2D Echo and the elevated 
TnI plasma concentration that occurred only in the first 
cardiac event may be justified by the long duration of the 
first vasospastic event.
Incidence and molecular mechanisms  
of cardiotoxicity
The chance for cardiac toxicity during fluoropyrimidines-
based treatment ranges from 1.2% to 18% with a mortal-
ity rate between 2.2% and 13.3%,27 although larger trials 
have suggested an incidence of symptomatic cardiotoxicity 
of 1.2%–4.3% during treatment. A large meta-analysis 
on breast and colorectal cancer patients treated with 
fluoropyrimidines28 confirmed this observation, revealing 
a similar low incidence (3%) of symptomatic 5-FU- and 
capecitabine-related events.
Interestingly, in a prospective study testing the poten-
tial development of cardiac-related symptoms during 
fluoropyrimidine-based chemotherapy, symptomatic ECG 
abnormalities were significantly more frequent in patients 
treated with 5-FU continuous 24-hour infusion and with capecit-
abine than in those receiving short infusion of 5-FU. On the 
other hand, no difference was observed between the incidence 
of capecitabine and 5-FU 24-hour infusion cardiotoxicity.29
The finding of a shared, schedule-associated toxic effect 
on myocardium is consistent with capecitabine pharmacody-
namics, with a prolonged exposure of tumor cells to the drug 
mimicking continuous intravenous 5-FU infusion.30 Even if 
5-FU plasma half-life is very short, active metabolites are 
retained at tissue level, both in tumor and in the heart, as 
demonstrated by pharmacokinetics studies.31
The mechanism of cardiotoxicity of fluoropyrimidines 
remains poorly defined. One of the documented causes of 
cardiotoxicity is the effect on vascular endothelium that 
involves endothelial nitric oxide (NO) synthase; 5-FU 
appeared to induce direct vasoconstriction on smooth 
muscle cells, which was shown to be protein kinase C-de-
pendent.32 A reduced synthesis of NO leads to coronary 
spasms and endothelium-independent vasoconstriction via 
the protein kinase pathway.33 However, it has been clari-
fied more than 20 years ago that neither calcium channel 
blockers34 nor nitrates35 can reduce the risk of fluoropy-
rimidines-related cardiotoxicity; thus, other pathogenic 
mechanisms need to be involved apart from the reduced 
concentration of NO.
Animal models provided the evidence of an increased 
endothelial thrombogenicity during 5-FU treatment, indicat-
ing a toxic effect of 5-FU on endothelial cells.36 Moreover, 
given the global systolic dysfunction related to fluoropyrimi-
dines cardiotoxicity, the possibility of a direct toxic action on 
the whole myocardium rather than focused coronary artery 
damages has also been evaluated.37 Recently, a preclinical 
model showed an apoptotic effect induced by the increase 
of intracellular reactive oxygen species in cardiomyocytes 
exposed to 5-FU. This observation suggested that 5-FU 
induces cardiomyocytes damage by oxidative stress.27
Synergic cardiotoxicity effect between capecitabine 
and other agents concomitantly administered has also been 
speculated. A retrospective study showed that cardiotoxicity 
was more frequently reported in patients receiving capecit-
abine plus taxanes than in those treated with capecitabine 
single agent (3.7% versus 1.9%), although the difference 
did not reach statistical significance.38 In our patient, cardiac 
toxicity was evident both in the TX schedule and in associa-
tion with lapatinib.
Risk factors for cardiotoxicity
Having a history of ischemic heart disease is the strongest pre-
disposing factor for fluoropyrimidines-induced cardiotoxicity.5 
A prospective cohort study conducted in 35 hospitals found 
that patients with preexisting cardiovascular disease have 
a significantly increased risk for cardiotoxicity (risk ratio 
[RR] =6.83) compared to those without baseline cardiac 
disease.39 Moreover, patients receiving concomitant calcium 
channel blockers (RR =4.75) and those receiving nitrates 
(RR =9.18) have an increased risk for  cardiotoxicity.39 The 
importance of preexisting cardiac disorders as a risk factor 
for cardiotoxicity was also highlighted in a retrospective 
studies specifically focused on capecitabine.38,40 The increased 
expression of thymidine phosphorylase, the key enzyme 
involved in the conversion of capecitabine to 5-FU, in both 
atherosclerotic plaques and tumor tissues41 may justify the 
higher prevalence of capecitabine-induced cardiotoxicity in 
patients with ischemic heart disorders.
Recently, a study focused on patients treated with 5-FU 
continuous 24-hour infusion showed that the complaint of 
chest or jaw pain and dyspnea in daily life during the first 
day of infusion is highly predictive of abnormalities during 
treadmill stress test.42
A link between cardiotoxicity and previous chest radio-
therapy or baseline renal function impairment has also been 
suggested.38 Conversely, no association with family history, 
hypertension, and smoking was found.29,38,43
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At the time of first diagnosis, our patient was a fully 
healthy young woman with no personal or familiar history 
of cardiac disease. After mastectomy she underwent irradia-
tion of the lymphatic drainage area, while excluding chest 
wall irradiation. Moreover, during metastatic treatment, the 
absence of atherosclerotic coronary artery disease was docu-
mented with coronary artery computed tomography and car-
diac magnetic resonance. In accordance with literature data, 
she had no established risk factors for fluoropyrimidines-
related cardiac toxicity; thus, there were no consistent reasons 
to avoid capecitabine treatment.
Clinical manifestation of cardiotoxicity
In a retrospective analysis of 688 patients consecutively 
treated for colorectal or gastric cancer, all cases of capecit-
abine cardiotoxicity occurred during the first cycle, with a 
median time for first occurrence of only 4 days from the start 
of treatment (range from 2 to 15 days).38
In 2011, Koca et al40 reported a 34.6% level of incidence 
for symptomatic cardiac events among 52 cancer patients 
treated with capecitabine either as single agent or in com-
bination with other drugs; palpitation (23.1%) and chest 
pain (9.6%) were the most common clinical manifestations. 
However, the percentage of patients who experienced symp-
tomatic toxicity significantly decreased in trials that involved 
a larger number of patients.29,38,43 Taken together, these trials 
showed an overall incidence of symptomatic cardiotoxicity 
from 4.0% to 6.5% and identified chest pain as the most fre-
quent reported symptom. Sudden cardiac death during fluo-
ropyrimidines treatment is a very rare event, accounting for 
less than 1% of cardiotoxicity clinical manifestation.29,43
Electrocardiographic abnormalities were documented 
by 12-lead ECG tracing in one study involving patients 
treated with capecitabine.40 One-third of patients (32.6%) 
were found to have new-onset ECG alterations: 25.0% ST 
segment deviation, 21.1% sinus tachycardia, and 19.2% 
prolonged QTc interval.
No study was conducted to assess the level of plasma 
troponins during capecitabine treatment. However, three 
studies44–46 were conducted in patients treated with 5-FU with 
discordant results; only Holubec et al46 reported a pathologic 
plasma TnI value (.0.04 ng/mL) in 57% of all enrolled 
patients, regardless of the presence of clinical symptoms.
Finally, data regarding 2D Echo modification reported in 
5-FU trials44,47 showed no significant changes in systolic and 
diastolic function during fluoropyrimidines treatment.
The clinical history of our patient suggests that capecit-
abine cardiotoxicity may present with different signs and 
symptoms, even in the same patient, and that the diagnosis 
may be challenging.
Rechallenge with capecitabine
Once cardiotoxicity has occurred, the safety of a rechal-
lenge with modified 5-FU- or capecitabine-based regimens 
is uncertain, and no widely accepted recommendations have 
been released.
In clinical practice, the reintroduction of a fluoropyrimidine-
based chemotherapy with dose reduction together with pro-
phylactic antianginal medications is quite common. However, 
even if the addition of anti-ischemic drugs, such as calcium 
channel blockers and nitrates, may reduce the clinical 
manifestations in some patients,48 the chemoprevention of 
cardiotoxicity with these agents is not definitively proved. For 
example, in a prospective study including 58 patients who 
received verapamil during 5-FU therapy, signs of ischemia 
using electrocardiography appeared as often as in a control 
group not receiving any antiangina drug.34
Since there are not large controlled trials that assessed 
the efficacy of antiangina therapy in this situation, whether 
the rechallenge is safe remains controversial49 and the option 
should be discussed on a case-by-case basis.
Conclusion
In the near future, the incidence of fluoropyrimidine-
induced cardiovascular side effects is expected to increase 
worldwide, because of the large use of these drugs in 
patients with breast or gastrointestinal cancers, the age-
ing of the population, and the higher frequency of cardiac 
comorbid condition in older subjects. The seriousness of 
this toxicity may vary widely, ranging from asymptomatic 
electrocardiographic alterations to life-threatening events. 
Overall, capecitabine cardiac toxicity is reported to affect 
nearly 5% of exposed patients, but this figure could under-
estimate the real incidence due to the underreporting of 
asymptomatic cases. Even in patients with clinical mani-
festations, capecitabine-induced cardiac toxicity may be 
an elusive side effect whose diagnosis is often challenging. 
Other than preexisting ischemic cardiac disorders, no well-
established risk factors have been identified. After a first 
cardiac episode (if mild-to-moderate in severity), fluoro-
pyrimidine rechallenge may be considered, but it should 
be proposed with great caution. Prophylactic treatment 
with coronary vasodilators does not seem to prevent such 
recurrences, although it is often used in clinical practice. 
If necessary, an active and thoughtful search of any signs 
or symptoms of cardiac ischemia should be applied. The 
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24-hour Holter monitoring on days 4–6 from the start of 
chemotherapy may be considered an effective and low-cost 
exam. Patients and caregivers should be educated about this 
side effect in order to maximize the chance of recognizing 
early clinical clues of cardiovascular impairment.  Moreover, 
patients should be advised to avoid unusual physical efforts, 
and to immediately report every cardiac symptom.
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